Federal policy makers are being confronted with increasingly critical of resource allocation to and within the health care sector. that the problems which have faced the End Stage Renal Disease are only symptomatic of more widespread problems that flow from new biomedical technologies and from a traditional national to the prolongation of life at any cost, the author addresses the of how needed health care macroallocation and microallocation are likely to be made. He discusses the use of cost-effectiveness cost-benefit analysis in assessing health practices and technologies, and general guidelines to be used in deciding whether to treat patients. (KIE abstract)
No takes yet. Share an insight, caveat, or question.
Roger W. Evans (1983) studied this question.